clinical trial · NCT03952806
Study of BHV-3241 in Participants With Multiple System Atrophy
Biohaven Pharmaceuticals, Inc.·phase3·completed·n = 421
Multiple System AtrophyVerdiperstatPlacebo
brief summary
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
started
Jul 29, 2019
primary completion
Jul 29, 2021
completion
Jun 30, 2022
last updated
Sep 29, 2023
official title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol